100% agreed that research access should be expanded, especially in light of the fact that these sort of drugs are unpredictable in their contents when obtained illicitly. Moving MDMA from schedule I to schedule II in the US would be a huge help. Despite my anecdotal warnings, its not a substance that doesnt merit further research.